At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATNF 180 Life Sciences Corp
Market Closed 11-01 16:00:00 EDT
3.74
-0.18
-4.59%
盘后3.70
-0.04-1.07%
19:57 EDT
High3.98
Low3.61
Vol159.63K
Open3.76
D1 Closing3.92
Amplitude9.48%
Mkt Cap3.84M
Tradable Cap3.33M
Total Shares1.03M
T/O601.30K
T/O Rate17.94%
Tradable Shares889.84K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
180 Life Sciences appoints Vaclav Vincalek as Senior Technology Consultant
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.